Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

Ralph A Defronzo, Luke Norton, Muhammad A Abdul-ghani

Research output: Contribution to journalReview article

101 Citations (Scopus)

Abstract

The kidney has a pivotal role in maintaining glucose homeostasis by using glucose as a metabolic fuel, by producing glucose through gluconeogenesis, and by reabsorbing all filtered glucose through the sodium-glucose cotransporters SGLT1 and SGLT2 located in the proximal tubule. In patients with diabetes, the maximum glucose reabsorptive capacity (Tm G) of the kidney, as well as the threshold for glucose spillage into the urine, are elevated, contributing to the pathogenesis of hyperglycaemia. By reducing the Tm G and, more importantly, the threshold of glucosuria, SGLT2 inhibitors enhance glucose excretion, leading to a reduction in fasting and postprandial plasma glucose levels and improvements in both insulin secretion and insulin sensitivity. The beneficial effects of SGLT2 inhibition extend beyond glycaemic control, however, with new studies demonstrating that inhibition of renal glucose reabsorption reduces blood pressure, ameliorates glucotoxicity and induces haemodynamic effects that lead to improved cardiovascular and renal outcomes in patients with type 2 diabetes mellitus. In this Review we examine the role of SGLT2 and SGLT1 in the regulation of renal glucose reabsorption in health and disease and the effect of SGLT2 inhibition on renal function, glucose homeostasis, and cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)11-26
Number of pages16
JournalNature Reviews Nephrology
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Kidney
Glucose
Homeostasis
Inhibition (Psychology)
Sodium-Glucose Transport Proteins
Gluconeogenesis
Hyperglycemia
Type 2 Diabetes Mellitus
Insulin Resistance
Fasting
Cardiovascular Diseases
Hemodynamics
Urine
Insulin
Blood Pressure
Health

ASJC Scopus subject areas

  • Nephrology

Cite this

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. / Defronzo, Ralph A; Norton, Luke; Abdul-ghani, Muhammad A.

In: Nature Reviews Nephrology, Vol. 13, No. 1, 01.01.2017, p. 11-26.

Research output: Contribution to journalReview article

Defronzo, Ralph A ; Norton, Luke ; Abdul-ghani, Muhammad A. / Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. In: Nature Reviews Nephrology. 2017 ; Vol. 13, No. 1. pp. 11-26.
@article{f5ab326d7a3c4fc2afe94e94030956f2,
title = "Renal, metabolic and cardiovascular considerations of SGLT2 inhibition",
abstract = "The kidney has a pivotal role in maintaining glucose homeostasis by using glucose as a metabolic fuel, by producing glucose through gluconeogenesis, and by reabsorbing all filtered glucose through the sodium-glucose cotransporters SGLT1 and SGLT2 located in the proximal tubule. In patients with diabetes, the maximum glucose reabsorptive capacity (Tm G) of the kidney, as well as the threshold for glucose spillage into the urine, are elevated, contributing to the pathogenesis of hyperglycaemia. By reducing the Tm G and, more importantly, the threshold of glucosuria, SGLT2 inhibitors enhance glucose excretion, leading to a reduction in fasting and postprandial plasma glucose levels and improvements in both insulin secretion and insulin sensitivity. The beneficial effects of SGLT2 inhibition extend beyond glycaemic control, however, with new studies demonstrating that inhibition of renal glucose reabsorption reduces blood pressure, ameliorates glucotoxicity and induces haemodynamic effects that lead to improved cardiovascular and renal outcomes in patients with type 2 diabetes mellitus. In this Review we examine the role of SGLT2 and SGLT1 in the regulation of renal glucose reabsorption in health and disease and the effect of SGLT2 inhibition on renal function, glucose homeostasis, and cardiovascular disease.",
author = "Defronzo, {Ralph A} and Luke Norton and Abdul-ghani, {Muhammad A}",
year = "2017",
month = "1",
day = "1",
doi = "10.1038/nrneph.2016.170",
language = "English (US)",
volume = "13",
pages = "11--26",
journal = "Nature Reviews Nephrology",
issn = "1759-507X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

AU - Defronzo, Ralph A

AU - Norton, Luke

AU - Abdul-ghani, Muhammad A

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The kidney has a pivotal role in maintaining glucose homeostasis by using glucose as a metabolic fuel, by producing glucose through gluconeogenesis, and by reabsorbing all filtered glucose through the sodium-glucose cotransporters SGLT1 and SGLT2 located in the proximal tubule. In patients with diabetes, the maximum glucose reabsorptive capacity (Tm G) of the kidney, as well as the threshold for glucose spillage into the urine, are elevated, contributing to the pathogenesis of hyperglycaemia. By reducing the Tm G and, more importantly, the threshold of glucosuria, SGLT2 inhibitors enhance glucose excretion, leading to a reduction in fasting and postprandial plasma glucose levels and improvements in both insulin secretion and insulin sensitivity. The beneficial effects of SGLT2 inhibition extend beyond glycaemic control, however, with new studies demonstrating that inhibition of renal glucose reabsorption reduces blood pressure, ameliorates glucotoxicity and induces haemodynamic effects that lead to improved cardiovascular and renal outcomes in patients with type 2 diabetes mellitus. In this Review we examine the role of SGLT2 and SGLT1 in the regulation of renal glucose reabsorption in health and disease and the effect of SGLT2 inhibition on renal function, glucose homeostasis, and cardiovascular disease.

AB - The kidney has a pivotal role in maintaining glucose homeostasis by using glucose as a metabolic fuel, by producing glucose through gluconeogenesis, and by reabsorbing all filtered glucose through the sodium-glucose cotransporters SGLT1 and SGLT2 located in the proximal tubule. In patients with diabetes, the maximum glucose reabsorptive capacity (Tm G) of the kidney, as well as the threshold for glucose spillage into the urine, are elevated, contributing to the pathogenesis of hyperglycaemia. By reducing the Tm G and, more importantly, the threshold of glucosuria, SGLT2 inhibitors enhance glucose excretion, leading to a reduction in fasting and postprandial plasma glucose levels and improvements in both insulin secretion and insulin sensitivity. The beneficial effects of SGLT2 inhibition extend beyond glycaemic control, however, with new studies demonstrating that inhibition of renal glucose reabsorption reduces blood pressure, ameliorates glucotoxicity and induces haemodynamic effects that lead to improved cardiovascular and renal outcomes in patients with type 2 diabetes mellitus. In this Review we examine the role of SGLT2 and SGLT1 in the regulation of renal glucose reabsorption in health and disease and the effect of SGLT2 inhibition on renal function, glucose homeostasis, and cardiovascular disease.

UR - http://www.scopus.com/inward/record.url?scp=85003855318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003855318&partnerID=8YFLogxK

U2 - 10.1038/nrneph.2016.170

DO - 10.1038/nrneph.2016.170

M3 - Review article

VL - 13

SP - 11

EP - 26

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-507X

IS - 1

ER -